A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy

Trial Profile

A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Bempedoic acid/ezetimibe (Primary) ; Bempedoic acid; Ezetimibe
  • Indications Cardiovascular disorders; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 02 Aug 2018 According to an Esperion Therapeutics media release, the company has a Global pivotal phase 3 LDL-C lowering program, consisting of five studies (Study 1, Study 2, Study 3 and Study 4 of bempedoic acid and 053 Study of bempedoic acid / ezetimibe combination pill).
    • 02 Aug 2018 According to an Esperion Therapeutics media release, top-line results from this study is expected in Aug 2018.
    • 23 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top